Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

(2020) John Timmerman et al.   AMERICAN JOURNAL OF HEMATOLOGY

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

(2020) Patrizia Mondello et al.   Cancer Discovery

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

(2020) Wenting Zhang et al.   Frontiers in Immunology

Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice

(2020) Sharmilla Devi Jayasingam et al.   Frontiers in Oncology

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma

(2020) Nathan H. Fowler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response

(2020) Wendy Béguelin et al.   CANCER CELL

Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma

(2020) Elie Dheilly et al.   CANCER CELL

Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma

(2020) Deepak Bararia et al.   Cell Reports

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

(2020) Xiaoguang Wang et al.   Protein & Cell

TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma

(2020) Zhi-Zhang Yang et al.   CLINICAL CANCER RESEARCH

Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies

(2020) Piotr Smolewski et al.   EXPERT OPINION ON PHARMACOTHERAPY

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies

(2020) Philippe Armand et al.   LEUKEMIA

Tim-3 finds its place in the cancer immunotherapy landscape

(2020) Nandini Acharya et al.   Journal for ImmunoTherapy of Cancer

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

(2020) Philippe Armand et al.   BLOOD

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

(2020) Franck Morschhauser et al.   LANCET ONCOLOGY

A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma

(2020) Pablo Mozas et al.   LEUKEMIA & LYMPHOMA

PI3Kδ inhibition reshapes follicular lymphoma–immune microenvironment cross talk and unleashes the activity of venetoclax

(2020) Neus Serrat et al.   Blood Advances

TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma

(2019) Sarah E Josefsson et al.   Cancer Immunology Research

PI3K Orchestrates T Follicular Helper Cell Differentiation in a Context Dependent Manner: Implications for Autoimmunity

(2019) Silvia Preite et al.   Frontiers in Immunology

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function

(2019) Stalin Chellappa et al.   JOURNAL OF IMMUNOLOGY

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

(2019) Ian W. Flinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of B cell/lymphoid stromal cell crosstalk in B-cell physiology and malignancy

(2019) Claire Lamaison et al.   IMMUNOLOGY LETTERS

Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia

(2019) Anna M Frustaci et al.   Future Oncology

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages

(2019) Antonin Papin et al.   LEUKEMIA

DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY

(2019) P. Perez Galan et al.   HEMATOLOGICAL ONCOLOGY

Fibroblastic reticular cells enhance T cell metabolism and survival via epigenetic remodeling

(2019) Flavian D. Brown et al.   NATURE IMMUNOLOGY

SIRPα expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma

(2019) Ya-Ping Chen et al.   Blood Cancer Journal

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL

(2019) Maissa Mhibik et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Microenvironment signaling driving lymphomagenesis

(2018) Léa Verdière et al.   CURRENT OPINION IN HEMATOLOGY

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

(2018) Antoine Italiano et al.   LANCET ONCOLOGY

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

(2018) Paul A. Hamlin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Single-cell RNA-Seq of lymphoma cancers reveals malignant B cell types and co-expression of T cell immune checkpoints

(2018) Noemi Andor et al.   BLOOD

CSF1R inhibitors exhibit anti-tumor activity in acute myeloid leukemia by blocking paracrine signals from support cells

(2018) David K. Edwards et al.   BLOOD

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530

(2018) Silvia L. Locatelli et al.   CLINICAL CANCER RESEARCH

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

(2018) Greg P. Coffey et al.   CLINICAL CANCER RESEARCH

T lymphocyte subsets in cancer immunity: Friends or foes

(2018) Dounia Chraa et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations

(2017) Koorosh Korfi et al.   Epigenetics

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium

(2017) Wendy B.C. Stevens et al.   HAEMATOLOGICA

EXPRESSION OF LAG-3 DEFINES EXHAUSTION OF INTRATUMORAL PD-1+ T CELLS AND CORRELATES WITH POOR OUTCOME IN FOLLICULAR LYMPHOMA

(2017) Z. Yang et al.   HEMATOLOGICAL ONCOLOGY

Ibrutinib treatment improves T cell number and function in CLL patients

(2017) Meixiao Long et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting of B-cell receptor signalling in B-cell malignancies

(2017) M. Jerkeman et al.   JOURNAL OF INTERNAL MEDICINE

Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors

(2017) Sarah J. Horton et al.   NATURE CELL BIOLOGY

A distinct subpopulation of CD25−T-follicular regulatory cells localizes in the germinal centers

(2017) James Badger Wing et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma

(2017) Jiyuan Zhang et al.   Cancer Discovery

Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding

(2017) Taghreed Hirz et al.   Oncotarget

Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study

(2017) Shing Fung Lee et al.   BMJ Open

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium

(2017) Wendy B.C. Stevens et al.   HAEMATOLOGICA

Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting

(2017) Nurit Hollander et al.   Frontiers in Immunology

Follicular lymphoma: evolving therapeutic strategies

(2016) B. S. Kahl et al.   BLOOD

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis

(2016) Wendy Béguelin et al.   CANCER CELL

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

(2016) Michael Boice et al.   CELL

Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma

(2016) Z. X. Ying et al.   CLINICAL CANCER RESEARCH

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

(2016) Yanwen Jiang et al.   Cancer Discovery

Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study

(2016) Robert Kridel et al.   PLOS MEDICINE

Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement

(2016) Pauline Gravelle et al.   OncoImmunology

Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells

(2015) A. Linley et al.   BLOOD

DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma

(2015) R. Amin et al.   BLOOD

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

(2015) Timothy S. Fenske et al.   CANCER

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma

(2015) A. M. Evens et al.   CLINICAL CANCER RESEARCH

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

(2015) R. Kridel et al.   CLINICAL CANCER RESEARCH

Fibroblastic Reticular Cells: Organization and Regulation of the T Lymphocyte Life Cycle

(2015) Flavian D. Brown et al.   JOURNAL OF IMMUNOLOGY

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

(2015) Alessandro Pastore et al.   LANCET ONCOLOGY

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma

(2015) Jessica Okosun et al.   NATURE GENETICS

Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis

(2015) Jiyuan Zhang et al.   NATURE MEDICINE

The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development

(2015) Ana Ortega-Molina et al.   NATURE MEDICINE

Novel immunotherapies in lymphoid malignancies

(2015) Connie Lee Batlevi et al.   Nature Reviews Clinical Oncology

The tumor microenvironment shapes hallmarks of mature B-cell malignancies

(2015) K H Shain et al.   ONCOGENE

Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation

(2015) Michael R. Green et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival

(2015) Z -Z Yang et al.   Blood Cancer Journal

Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas

(2015) Murielle Grégoire et al.   Oncotarget

Several immune escape patterns in non-Hodgkin's lymphomas

(2015) Camille Laurent et al.   OncoImmunology

CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma

(2015) Ana M. Martín-Moreno et al.   PLoS One

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma

(2014) I. W. Flinn et al.   BLOOD

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

(2014) Michinori Ogura et al.   BRITISH JOURNAL OF HAEMATOLOGY

Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

(2014) A. Matas-Cespedes et al.   CLINICAL CANCER RESEARCH

t(14;18) Translocation: A Predictive Blood Biomarker for Follicular Lymphoma

(2014) Sandrine Roulland et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetics of Follicular Lymphoma Transformation

(2014) Laura Pasqualucci et al.   Cell Reports

Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma

(2013) M. R. Green et al.   BLOOD

EZH2 mutations are frequent and represent an early event in follicular lymphoma

(2013) C. Bodor et al.   BLOOD

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells

(2013) J. H. Myklebust et al.   BLOOD

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma

(2013) Michelle Fanale et al.   BRITISH JOURNAL OF HAEMATOLOGY

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

(2013) Wendy Béguelin et al.   CANCER CELL

Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function: Potential Impact on Survival and Risk of Transformation

(2013) Shahryar Kiaii et al.   JOURNAL OF CLINICAL ONCOLOGY

Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment

(2013) S. Rawal et al.   JOURNAL OF IMMUNOLOGY

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

(2013) Reina Watanabe et al.   LEUKEMIA RESEARCH

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

(2013) Jessica Okosun et al.   NATURE GENETICS

The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity

(2013) Patricia Amé-Thomas et al.   SEMINARS IN CANCER BIOLOGY

Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes

(2012) F. Guilloton et al.   BLOOD

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

(2012) Sarah K Knutson et al.   Nature Chemical Biology

Myeloid cells

(2012) Benjamin Toh et al.   OncoImmunology

The microenvironment in follicular lymphoma

(2011) Daphne de Jong et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study

(2011) C. Laurent et al.   BLOOD

Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling

(2011) D. A. Hume et al.   BLOOD

Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma

(2011) Madhavi Challa-Malladi et al.   CANCER CELL

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

(2011) Mark Kirschbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis

(2011) E Launay et al.   LEUKEMIA

Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells

(2011) P Amé-Thomas et al.   LEUKEMIA

Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling

(2011) G Epron et al.   LEUKEMIA

The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma

(2011) Ryan A. Wilcox et al.   LEUKEMIA & LYMPHOMA

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE

Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment

(2010) A. J. Clear et al.   BLOOD

Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis

(2010) K.-J. J. Cheung et al.   CANCER RESEARCH

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

(2010) Alberto Mantovani et al.   CURRENT OPINION IN IMMUNOLOGY

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

(2010) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis

(2010) C Pangault et al.   LEUKEMIA

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

(2010) C. J. Sneeringer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation

(2009) P. Farinha et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma

(2009) Joaquim Carreras et al.   JOURNAL OF CLINICAL ONCOLOGY

Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment

(2008) G. Cartron et al.   ANNALS OF ONCOLOGY

High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial

(2007) Danielle Canioni et al.   JOURNAL OF CLINICAL ONCOLOGY